Effects of lacosamide “a novel antiepileptic drug” in the early stages of chicken embryo development

Simple item page
dc.contributor.authorMete M.
dc.contributor.authorGurcu B.
dc.contributor.authorCollu F.
dc.contributor.authorUnsal U.U.
dc.contributor.authorDuransoy Y.K.
dc.contributor.authorTuglu M.I.
dc.contributor.authorSelcuki M.
dc.date.accessioned2024-07-22T08:11:32Z
dc.date.available2024-07-22T08:11:32Z
dc.date.issued2016
dc.description.abstractIntroduction: Antiepileptic drugs (AEDs) are teratogens and confer a risk of congenital malformation. The estimated prevalence of major congenital malformations such as cardiac defects, facial clefts, hypospadias, and neural tube defects in epileptic women is 4–10 %, which represents a two- to fourfold increase in pregnant women compared to the general population. However, there are no clear data for newer drugs. Lacosamide (LCM), a novel AED, is the first of the third-generation AEDs to be approved as adjunctive therapy for the treatment of partial-onset seizures. There are no data on the pharmacokinetics of LCM during pregnancy, and only some published data have reported on its effects during pregnancy. Methods: In this study, three different doses of LCM (0.12, 0.5, and 1.60 mg in 0.18 mL) were applied under the embryonic disks of specific pathogen-free Leghorn chicken embryos after a 30-h incubation. Incubation was continued for 80 h, at which time all embryos were evaluated macroscopically and microscopically. Results: There was growth retardation in all of the LCM-treated groups. Major malformations increased in a dose-dependent manner and were mostly observed in the supratherapeutic group. Conclusion: Based on our data, LCM may cause growth retardation or major congenital malformations. Nevertheless, more extensive investigations of its reliability are needed. © 2016, Springer-Verlag Berlin Heidelberg.
dc.identifier.DOI-ID10.1007/s00381-016-3181-4
dc.identifier.issn02567040
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15681
dc.language.isoEnglish
dc.publisherSpringer Verlag
dc.subjectAcetamides
dc.subjectAnimals
dc.subjectAnticonvulsants
dc.subjectChick Embryo
dc.subjectDose-Response Relationship, Drug
dc.subjectEmbryonic Development
dc.subjectFemale
dc.subjectFetal Growth Retardation
dc.subjectNervous System Malformations
dc.subjectPregnancy
dc.subjectlacosamide
dc.subjectacetamide derivative
dc.subjectanticonvulsive agent
dc.subjectlacosamide
dc.subjectArticle
dc.subjectchick embryo
dc.subjectcongenital malformation
dc.subjectcontrolled study
dc.subjectdevelopmental stage
dc.subjectdrug effect
dc.subjectembryo
dc.subjectembryo development
dc.subjectgrowth retardation
dc.subjectLeghorn chicken
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectanimal
dc.subjectchemically induced
dc.subjectdose response
dc.subjectdrug effects
dc.subjectembryo development
dc.subjectfemale
dc.subjectFetal Growth Retardation
dc.subjectNervous System Malformations
dc.subjectphysiology
dc.subjectpregnancy
dc.titleEffects of lacosamide “a novel antiepileptic drug” in the early stages of chicken embryo development
dc.typeArticle

Files

Collections

Scopus Koleksiyonu